BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Sep 9, 2020
Product Development

NIH’s Pérez-Stable outlines ways biopharmas can address racial disparities in healthcare: a BioCentury audio interview

Eliseo Pérez-Stable, director of NIH’s National Institute on Minority Health and Health Disparities, says the information on racial and minority ethnic disparities in healthcare is out there, it’s...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

The growing demand for asymptomatic COVID-19 testing is shifting the conversation from one-time diagnosis to ongoing screening, and from single results to population outcomes. Companies moving the ball forward for early detection of cancer, some...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...Phase II EMPhASIS trial. The DHODH inhibitor reduced the number of combined unique active magnetic resonance...
BioCentury | May 14, 2020
Politics, Policy & Law

By selecting McMurry-Heath as new leader, BIO breaks mold

BIO has picked a new president and CEO, Michelle McMurry-Heath, who breaks the Washington trade association mold. She will take over on June 1 from Jim Greenwood, who has held the position since 2004; she...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...MRI is significant.” Yusuf Yazici, Samumed   At least three companies are betting on magnetic resonance...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
Items per page:
1 - 10 of 605
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed. Launched in 2019 by...
BioCentury | Dec 5, 2020
Politics, Policy & Law

Trump administration uses last days to undermine public health agencies

Senior Trump administration officials are spending their last weeks in office throwing sand into the gears of government, gumming up the operation of public health agencies and dismantling protections against political interference in the actions...
BioCentury | Nov 17, 2020
Product Development

Moderna times & China’s future: a BioCentury podcast

Now that Moderna and partners BioNTech and Pfizer have set the bar for efficacy in COVID-19 vaccines, what’s next for the rest of players in the hunt? On the latest edition of the BioCentury This...
BioCentury | Oct 3, 2020
Politics, Policy & Law

Congressional Democrats rehearse drug pricing attacks

Leaders of some of the world’s leading biopharma companies faced off last week against congressional Democrats – and were soundly defeated. The two-day hearing on drug pricing convened by the House Oversight...
BioCentury | Sep 9, 2020
Product Development

NIH’s Pérez-Stable outlines ways biopharmas can address racial disparities in healthcare: a BioCentury audio interview

Eliseo Pérez-Stable, director of NIH’s National Institute on Minority Health and Health Disparities, says the information on racial and minority ethnic disparities in healthcare is out there, it’s...
BioCentury | Aug 8, 2020
Product Development

Asymptomatic COVID-19 testing pushes forward, with lessons from cancer

The growing demand for asymptomatic COVID-19 testing is shifting the conversation from one-time diagnosis to ongoing screening, and from single results to population outcomes. Companies moving the ball forward for early detection of cancer, some...
BioCentury | Aug 4, 2020
Product Development

Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more

...Phase II EMPhASIS trial. The DHODH inhibitor reduced the number of combined unique active magnetic resonance...
BioCentury | May 14, 2020
Politics, Policy & Law

By selecting McMurry-Heath as new leader, BIO breaks mold

BIO has picked a new president and CEO, Michelle McMurry-Heath, who breaks the Washington trade association mold. She will take over on June 1 from Jim Greenwood, who has held the position since 2004; she...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...MRI is significant.” Yusuf Yazici, Samumed   At least three companies are betting on magnetic resonance...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
Items per page:
1 - 10 of 605